Lv7
5000 积分 2023-10-17 加入
Outcomes After Neoadjuvant Targeted Therapy in Patients with ALK or ROS1 Rearrangement Locally Advanced Non-small Cell Lung Cancer
12天前
已完结
Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report
12天前
已完结
[Expert Consensus on Rational Use and Monitoring of Small Molecule Targeted Drugs for Lung Cancer]
15天前
已完结
Lung Cancer: Targeted Therapy in 2025
15天前
已完结
皖公网安备34019202002308
